With resignations of top leaders, Cassava Sciences exposes a dark, ugly corner of the Alzheimer’s disease world

Cassava Sciences is imploding — and as it crumbles, a dark, ugly corner of the Alzheimer’s disease world is being exposed and will hopefully get cleaned up.

Remi Barbier, Cassava’s longtime CEO, has resigned and is also leaving the board, the company announced Wednesday. Lindsay Burns, Cassava’s senior vice president of neuroscience, is gone, too. She is married to Barbier.

Their abrupt departures come after the ​​Justice Department, on June 28, charged the company’s chief scientific collaborator and paid consultant, Hoau-Yan Wang, with multiple counts of fraud related to grants supporting Cassava’s experimental Alzheimer’s drug, called simufilam.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $399/year

$30 for 3 months Get Started

Then $399/year

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

To read the rest of this story subscribe to STAT+.

Subscribe

Log In